Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: From the active site to the second phosphotyrosine binding site

Journal of Medicinal Chemistry

Volumn 50, Issue 19, 2007, Pages 4681-4698

  Wilson, Douglas P ^a   Wan, Zhao Kui ^a   Xu, Wei Xin ^a   Kirincich, Steven J ^a   Follows, Bruce C ^a   Joseph McCarthy, Diane ^a   Foreman, Kenneth ^a,c   Moretto, Alessandro ^a   Wu, Junjun ^a   Zhu, Min ^a   Binnun, Eva ^a   Zhang, Yan Ling ^a,d   Tam, May ^a   Erbe, David V ^a   Tobin, James ^a   Xu, Xin ^a   Leung, Louis ^a   Shilling, Adam ^a   Tam, Steve Y ^a   Mansour, Tarek S ^a,b   Lee, Jinbo ^a,e   more..

^a PFIZER INC   (United States)

^b WYETH RESEARCH   (United States)

^c OSI PHARMACEUTICALS INC   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Ensemble Discovery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN RECEPTOR; LEPTIN RECEPTOR; PHOSPHOTYROSINE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG BINDING SITE; ENZYME ACTIVE SITE; ENZYME INHIBITION; MALE; MOLECULAR MODEL; MOUSE; NONHUMAN; OBESITY; RAT; STRUCTURE ANALYSIS; X RAY ANALYSIS;

ANIMALS; BINDING SITES; CACO-2 CELLS; CATALYTIC DOMAIN; CELL MEMBRANE PERMEABILITY; CRYSTALLOGRAPHY, X-RAY; HALF-LIFE; HEPATOCYTES; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHOTYROSINE; PROTEIN-TYROSINE-PHOSPHATASE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES; TISSUE DISTRIBUTION;

EID: 34648833338     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0702478     Document Type: Article

References (42)

1. Asante-Appiah, E.; Kennedy, B. P. Protein tyrosine phosphatases: The quest for negative regulators of insulin action. Am. J. Physiol. 2003, 284, E663-E670.
2. Cook, W. S.; Unger, R. H. Protein tyrosine phosphatase 1B: A potential leptin resistance factor of obesity. Dev. Cell 2002, 2, 385-387.
3. Byon, J. C. H.; Kusari, A. B.; Kusari, J., Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction. Mol. Cell. Biochem. 1998, 182, 101-108.
4. Cheng, A.; Tremblay, M. L. Insulin receptor PTP: PTP1B. Handb. Cell Signal. 2004, 1, 729-732.
5. Elchebly, M.; Payette, P.; Michaliszyn, E.; Cromlish, W.; Collins, S.; Loy, A. L.; Normandin, D.; Cheng, A.; Himms-Hagen, J.; Chan, C. C.; Ramachandran, C.; Gresser, M. J.; Tremblay, M. L.; Kennedy, B. P. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999, 283, 1544-1548.
6. Klaman, L. D.; Boss, O.; Peroni, O. D.; Kim, J. K.; Martino, J. L.; Zabolotny, J. M.; Moghal, N.; Lubkin, M.; Kim, Y. B.; Sharpe, A. H.; Stricker-Krongrad, A.; Shulman, G. I.; Neel, B. G.; Kahn, B. B. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell. Biol. 2000, 20, 5479-5489.
7. Zinker, B. A.; Rondinone, C. M.; Trevillyan, J. M.; Gum, R. J.; Clampit, J. E.; Waring, J. F.; Xie, N.; Wilcox, D.; Jacobson, P.; Frost, L.; Kroeger, P. E.; Reilly, R. M.; Koterski, S.; Opgenorth, T. J.; Ulrich, R. G.; Crosby, S.; Butler, M.; Murray, S. F.; McKay, R. A.; Bhanot, S.; Monia, B. P.; Jirousek, M. R. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 11357-11362.
8. Gum, R. J.; Gaede, L. L.; Koterski, S. L.; Heindel, M.; Clampit, J. E.; Zinker, B. A.; Trevillyan, J. M.; Ulrich, R. G.; Jirousek, M. R.; Rondinone, C. M. Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice. Diabetes 2003, 52, 21-28.
9. Hansen, S. K.; Cancilla, M. T.; Shiau, T. P.; Kung, J.; Chen, T.; Erlanson, D. A. Allosteric inhibition of PTP1B activity by selective modification of a non-active site cysteine residue. Biochemistry 2005, 44, 7704-7712.
10. Zhang, Z.-Y.; Lee, S.-Y. PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. Exp. Opin. Invest. Drug. 2003, 12, 223-233.
11. Tonks, N. K., PTP1B: From the sidelines to the front lines! FEBS Lett. 2003, 546, 140-148.
12. Andersen, H. S.; Olsen, O. H.; Iversen, L. F.; Sorensen, A. L. P.; Mortensen, S. B.; Christensen, M. S.; Branner, S.; Hansen, T. K.; Lau, J. F.; Jeppesen, L.; Moran, E. J.; Su, J.; Bakir, F.; Judge, L.; Shahbaz, M.; Collins, T.; Vo, T.; Newman, M. J.; Ripka, W. C.; Moller, N. P. H. Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B. J. Med. Chem. 2002, 45, 4443-4459.
13. Dufresne, C.; Roy, P.; Wang, Z.; Asante-Appiah, E.; Cromlish, W.; Boie, Y.; Forghani, F.; Desmarais, S.; Wang, Q.; Skorey, K.; Waddleton, D.; Ramachandran, C.; Kennedy, B. P.; Xu, L.; Gordon, R.; Chan, C. C.; Leblanc, Y. The development of potent non-peptidic PTP-1B inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 1039-1042.
14. Larsen, S. D.; Stevens, F. C.; Lindberg, T. J.; Bodnar, P. M.; O'Sullivan, T. J.; Schostarez, H. J.; Palazuk, B. J.; Bleasdale, J. E. Modification of the N-terminus of peptidomimetic protein tyrosine phosphatase 1B (PTP1B) inhibitors: Identification of analogues with cellular activity. Bioorg. Med. Chem. Lett. 2003, 13, 971-975.
15. Lau, C. K.; Bayly, C. I.; Gauthier, J. Y.; Li, C. S.; Therien, M.; Asante-Appiah, E.; Cromlish, W.; Boie, Y.; Forghani, F.; Desmarais, S.; Wang, Q.; Skorey, K.; Waddleton, D.; Payette, P.; Ramachandran, C.; Kennedy, B. P.; Scapin, G. Structure based design of a series of potent and selective non peptidic PTP-1B inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 1043-1048.
16. Liu, G.; Xin, Z.; Liang, H.; Abad-Zapatero, C.; Hajduk, P. J.; Janowick, D. A.; Szczepankiewicz, B. G.; Pei, Z.; Hutchins, C. W.; Ballaron, S. J.; Stashko, M. A.; Lubben, T. H.; Berg, C. E.; Rondinone, C. M.; Trevillyan, J. M.; Jirousek, M. R. Selective protein tyrosine phosphatase 1B inhibitors: Targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands. J. Med. Chem. 2003, 46, 3437-3440.
17. Zhao, H.; Liu, G.; Xin, Z.; Serby, M. D.; Pei, Z.; Szczepankiewicz, B. G.; Hajduk, P. J.; Abad-Zapatero, C.; Hutchins, C. W.; Lubben, T. H.; Ballaron, S. J.; Haasch, D. L.; Kaszubska, W.; Rondinone, C. M.; Trevillyan, J. M.; Jirousek, M. R. Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 5543-5546.
18. Shen, K.; Keng, Y. F.; Wu, L.; Guo, X. L.; Lawrence, D. S.; Zhang, Z. Y. Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure. J. Biol. Chem. 2001, 276, 47311-9.
19. Johnson, T. O.; Ermolieff, J.; Jirousek, M. R. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat. Rev. Drug Discovery 2002, 1, 696-709.
20. Liu, G. Protein tyrosine phosphatase 1B inhibition: Opportunities and challenges. Curr. Med. Chem. 2003, 10, 407-1421.
21. Tobin, J. F.; Tam, S. Recent advances in the development of small molecule inhibitors of PTP1B for the treatment of insulin resistance and type 2 diabetes. Curr. Opin. Drug Discovery Dev. 2002, 5, 500-512.
22. Andersen, J. N.; Tonks, N. K. Protein tyrosine phosphatase-based therapeutics: Lessons from PTP1B. Top. Curr. Genet. 2004, 5, 201-230.
23. Montalibet, J.; Kennedy, B. P. Therapeutic strategies for targeting PTP1B in diabetes. Drug Discovery Today: Ther. Strategies 2005, 2, 129-135.
24. Moretto, A. F.; Kirincich, S. J.; Xu, W. X.; Smith, M. J.; Wan, Z.-K.; Wilson, D. P.; Follows, B. C.; Binnun, E.; Joseph-McCarthy, D.; Foreman, K.; Erbe, D. V.; Zhang, Y. L.; Tam, S. K.; Tam, S. Y.; Lee, J. Bicyclic and tricyclic thiophenes as protein tyrosine phosphatase 1B inhibitors. Bioorg. Med. Chem. 2006, 14, 2162-2177.
25. Wan, Z.-K.; Lee, J.; Xu, W. X.; Erbe, D. V.; Joseph-McCarthy, D.; Follows, B. C.; Zhang, Y. L. Monocyclic thiophenes as protein tyrosine phosphatase 1B inhibtors: Capturing interactions with Asp48. Bioorg. Med. Chem. Lett. 2006, 16, 4941-4945.
26. Iversen, L. F.; Andersen, H. S.; Moller, K. B.; Olsen, O. H.; Peters, G. H.; Branner, S.; Mortensen, S. B.; Hansen, T. K.; Lau, J.; Ge, Y.; Holsworth, D. D.; Newman, M. J.; Hundahl Moller, N. P. Steric hindrance as a basis for structure-based design of selective inhibitors of protein-tyrosine phosphatases. Biochemistry 2001, 40, 14812-20.
27. Puius, Y. A.; Zhao, Y.; Sullivan, M.; Lawrence, D. S.; Almo, S. C.; Zhang, Z. Y. Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: A paradigm for inhibitor design. Proceed. Natl. Acad. Sci. U.S.A. 1997, 94, 13420-13425.
28. Asante-Appiah, E.; Patel, S.; Dufresne, C.; Roy, P.; Wang, Q.; Patel, V.; Friesen, R. W.; Ramachandran, C.; Becker, J. W.; Leblanc, Y.; Kennedy, B. P.; Scapin, G. The structure of PTP-1B in complex with a peptide inhibitor reveals an alternative binding mode for bisphosphonates. Biochemistry 2002, 41, 9043-9051.
29. Szczepankiewicz, B. G.; Liu, G.; Hajduk, P. J.; Abad-Zapatero, C.; Pei, Z.; Xin, Z.; Lubben, T. H.; Trevillyan, J. M.; Stashko, M. A.; Ballaron, S. J.; Liang, H.; Huang, F.; Hutchins, C. W.; Fesik, S. W.; Jirousek, M. R. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J. Am. Chem. Soc. 2003, 125, 4087-4096.
30. Smith, M. B.; March, J. March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th ed.; Wiley: New York, 2000; 1824 pp.
31. Baxter, E. W.; Reitz, A. B. Reductive aminations of carbonyl compounds with borohydride and borane reducing agents. Org. React. (New York) 2002, 59, 1-714.
32. Abdel-Magid, A. F.; Maryanoff, C. A. Use of sodium triacetoxyborohydride in reductive amination of ketones and aldehydes. ACS Symp. Ser. 1996, 641 (Reductions in Organic Synthesis), 201-216.
33. Corral, C.; Lissavetzky, J. Reactions with 3-hydroxy-2-(methoxy-carbonyl) thiophene; I. Synthesis of 3-thienyloxyacetic acid and its (nuclear) chloro and bromo derivatives. Synthesis 1984, (10), 847-50.
34. Pedersen, A. K.; Peters, G. u. H.; Moller, K. B.; Iversen, L. F.; Kastrup, J. S. Water-molecule network and active-site flexibility of apo protein tyrosine phosphatase 1B. Acta Crystallogr. Sect. D: Biol. Crystallogr. 2004, D60, 1527-1534.
35. Scapin, G.; Patel, S.; Patel, V.; Kennedy, B.; Asante-Appiah, E. The structure of apo protein-tyrosine phosphatase 1B C215S mutant: More than just an S → O change. Protein Sci. 2001, 10, 1596-1605.
36. Iversen, L. F.; Moller, K. B.; Pedersen, A. K.; Peters, G. H.; Petersen, A. S.; Andersen, H. S.; Branner, S.; Mortensen, S. B.; Moller, N. P. H. Structure determination of T cell protein-tyrosine phosphatase. J. Biol. Chem. 2002, 277, 19982-19990.
37. Cvetkovic, M.; Leake, B.; Fromm. M. F.; Wilkinson, G. R.; Kim, R. B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 1999, 27, 866-871.
38. Shimizu, M.; Fuse, K.; Okudaira, K.; Nishigaki, R.; Maeda, K.; Kusuhara, H.; Sugiyama, Y. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos. 2005, 33, 1477-1481.
39. Poirier, A.; Funk, C.; Lave, T.; Noe J. New strategies to address drug - drug interactions involving OATPs. Curr. Opin. Drug Discovery Dev. 2007, 10, 74-83.
40. Corral, C.; Lissavetzky, J.; Manzanares, I. Effects of substituents on the chlorination of methyl 3-hydroxythiophene-2-carboxylate and on the reaction of the resulting chlorinated products with active hydrogen containing compounds. J. Heterocycl. Chem. 1990, 27, 315-319.
41. Hoppe, E.; Berne, P.-F.; Stock, D.; Rasmussen, J. S.; Moeller, N. P. H.; Ullrich, A.; Huber, R. Expression, purification and crystallization of human phosphotyrosine phosphatase 1B. Eur. J. Biochem. 1994, 223, 1069-1077.
42. McMartin, C.; Bohacek, R. S. QXP: Powerful, rapid computer algorithms for structure-based drug design. J. Comput.-Aided Mol. Design 1997, 11, 333-344.